NEW YORK, August 18, 2017 /PRNewswire/ --
If you want a Stock Review on OCUL, OMER, OVAS, or RGLS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, August 17, 2017, US markets saw broad based losses with nine out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,221.91, down 1.94%; the Dow Jones Industrial Average edged 1.24% lower, to finish at 21,750.73; and the S&P 500 closed at 2,430.01, down 1.54%. This Friday morning, DailyStockTracker.com looks at the performance of these four Biotechnology stocks: Ocular Therapeutix Inc. (NASDAQ: OCUL), Omeros Corp. (NASDAQ: OMER), OvaScience Inc. (NASDAQ: OVAS), and Regulus Therapeutics Inc. (NASDAQ: RGLS). This morning's free research reports on the aforesaid equities can be accessed upon registration on DailyStockTracker.com at:
On Thursday, shares in Bedford, Massachusetts headquartered Ocular Therapeutix Inc. recorded a trading volume of 262,311 shares. The stock ended the session 0.69% higher at $5.84. The stock is trading below its 50-day moving average by 27.24%. Moreover, shares of Ocular Therapeutix, which focuses on the development, manufacture, and commercialization of ocular therapies using its HYDROME technology, have a Relative Strength Index (RSI) of 36.02.
On July 26th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $10 per share. Visit us today and download your complete report on OCUL for free at:
Seattle, Washington-based Omeros Corp.'s stock closed the day 1.14% lower at $22.48 with a total trading volume of 518,248 shares. The Company's shares have advanced 36.74% in the previous three months, 99.29% over the last twelve months, and 126.61% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.53% and 53.02%, respectively. Additionally, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 49.19. The complimentary research report on OMER can be accessed at:
Shares in Waltham, Massachusetts headquartered OvaScience Inc. recorded a trading volume of 47,800 shares. The stock ended yesterday's trading session 2.74% higher at $1.50. The Company's shares have advanced 12.78% over the previous three months. The stock is trading below its 50-day moving average by 0.34%. Furthermore, shares of OvaScience, which discovers, develops, and commercializes fertility treatment options for women worldwide, have an RSI of 49.57. Register for free on DailyStockTracker.com and download the research report on OVAS at:
San Diego, California headquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 1.89% lower at $0.87 with a total trading volume of 457,393 shares. The stock is trading below its 50-day moving average by 14.35%. Additionally, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 41.49. Get free access to your research report on RGLS at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA